US FDA’s Two-Month Safety Window For COVID Vaccines Based On Adverse Events In Other Products
Executive Summary
In remarks fleshing out the ‘EUA Plus’ guidance before it became a political football, Operation Warp Speed’s Slaoui said that an FDA analysis concluded that 90% of adverse events related to vaccination take place within the first 42 days.
You may also be interested in...
Pfizer’s Bourla: State of US Presidential Transition Not ‘Ideal’ For Vaccine Rollout
Pfizer and BioNTech have accumulated enough safety data to submit an emergency use authorization, and Pfizer CEO Bourla says at the Stat Summit that he is ‘comfortable’ US distribution of the vaccine will go well despite the unusually complicated government transition.
After EUA, COVID Vaccine Sponsors Need Plans For Continuing Trials
EUA request should also include plan for a sponsor’s active follow-up for safety among individuals given the vaccine under EUA – including assessing deaths, hospitalizations and other clinically significant adverse events – to inform ongoing benefit-risk determinations to support the continued authorization, US FDA says in its finally-released guidance.
Transparency, And A Mirror: US FDA Advice On COVID-19 Vaccine EUAs Finally Published – Twice
Everyone but Donald Trump seems happy that the guidance is finally here, with release appearing to be driven by FDA's disclosure of advisory committee materials.